» Articles » PMID: 16484334

Method to Evaluate the Dustiness of Pharmaceutical Powders

Overview
Journal Ann Occup Hyg
Date 2006 Feb 18
PMID 16484334
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

The trend among pharmaceutical companies to develop selective drugs of high potency has pushed the industry to consider the potential of each hazardous ingredient to become airborne. Dustiness issues are not unique to the pharmaceutical industry, but are relevant to any industry where powdered materials are mixed, transferred and handled. Interest in dustiness is also driven by concerns for worker health, the potential for plant explosions and the prevention of product loss. Unlike other industries, the pharmaceutical industry is limited by the milligram quantity of powdered material available for testing during product development. These needs have led to the development of a bench-top dustiness tester that requires only 10 mg of powder and fully contains the generated aerosol. The powder is dispersed within a 5.7 liter glass chamber that contains a respirable mass sampler and a closed-face sampler to quantify the respirable and total dust that are generated with a given energy input. The tester distinguished differences in dustiness levels of five different powders. Finer powders were dustier, and the respirable dust percentage was always less than that for total dust. Four testers have been built and evaluated using pharmaceutical grade lactose. Dustiness measurements determined using all four testers were comparable. The pharmaceutical industry uses surrogates such as lactose to represent active compounds in tests that estimate the dust concentration likely to occur in a new manufacturing operation. Differences between the dustiness of the active compound and its surrogate challenge the relevance of the surrogate tests to represent true exposures in the workplace. The tester can determine the dustiness of both the active compound and its surrogate, and the resultant ratio can help to interpret dust concentrations from surrogate tests. Further, dustiness information may allow the pharmaceutical researcher to select powder formulations that present low airborne concentrations in the workplace.

Citing Articles

An Investigation on the Relationship between Dust Emission and Air Flow as Well as Particle Size with a Novel Containment Two-Chamber Setup.

Wirth S, Scholer M, Brugmann J, Leopold C Pharmaceutics. 2024; 16(8).

PMID: 39204433 PMC: 11359288. DOI: 10.3390/pharmaceutics16081088.


Computational Fluid Dynamics Simulations of Aerosol Behavior in a High Speed (Heubach) Rotating Drum Dustiness Tester.

Chen H, Jog M, Turkevich L Particuology. 2023; 72:68-80.

PMID: 37207251 PMC: 10193456. DOI: 10.1016/j.partic.2022.02.010.


A Novel Two-Chamber Setup for Containment Investigations with Special Focus on the Dustiness of Pharmaceutical Powders Depending on the Airflow.

Wirth S, Scholer M, Brugmann J, Leopold C Pharmaceutics. 2022; 14(11).

PMID: 36365205 PMC: 9696387. DOI: 10.3390/pharmaceutics14112387.


Numerical Investigation of Aerosolization in the Venturi Dustiness Tester: Aerodynamics of a Particle on a Hill.

Palakurthi N, Ghia U, Turkevich L J Fluids Eng. 2022; 144(6).

PMID: 35673360 PMC: 9170177. DOI: 10.1115/1.4054099.


Evaluation of total and inhalable samplers for the collection of carbon nanotube and carbon nanofiber aerosols.

Dahm M, Evans D, Bertke S, Grinshpun S Aerosol Sci Technol. 2022; 53(8):958-970.

PMID: 35392279 PMC: 8985588. DOI: 10.1080/02786826.2019.1618437.